Standard BioTools Inc. Research and Development Expense
Standard BioTools Inc. (LAB) reported Research and Development Expense of $1.98 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- Standard BioTools Inc. research and development expense for the quarter ending 2026-06-30 was $1.98M, a 68.24% decline year-over-year.
- Standard BioTools Inc. research and development expense for the quarter ending 2026-03-31 was $2.12M, a 61.08% decline year-over-year.
- Standard BioTools Inc. research and development expense for the quarter ending 2025-12-31 was $7.97M, a 13.20% increase year-over-year.
- Standard BioTools Inc. research and development expense for the quarter ending 2025-09-30 was $6.36M, a 8.40% decline year-over-year.
- Standard BioTools Inc. research and development expense for fiscal 2025 was $25.99M, a 9.86% decline from fiscal 2024.
- Standard BioTools Inc. research and development expense for fiscal 2024 was $28.83M, a 11.11% increase from fiscal 2023.
- Standard BioTools Inc. research and development expense for fiscal 2023 was $25.95M, a 30.59% decline from fiscal 2022.
- Standard BioTools Inc. research and development expense for fiscal 2022 was $37.38M, a 1.48% decline from fiscal 2021.
| Period end | Research and Development Expense 1 month | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.98M 10-Q · filed 2026-08-05 | $4.09M 10-Q · filed 2026-08-05 | $12.06M derived: sum of 3 quarters · filed 2026-08-05 | $18.42M derived: sum of 4 quarters · filed 2026-08-05 | |||||
| 2026-03-31 | $2.12M 10-Q · filed 2026-05-06 | $10.09M derived: sum of 2 quarters · filed 2026-05-06 | $16.44M derived: sum of 3 quarters · filed 2026-05-06 | $22.66M derived: sum of 4 quarters · filed 2026-08-05 | |||||
| 2025-12-31 | $7.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $14.32M derived: sum of 2 quarters · filed 2026-03-16 | $20.55M derived: sum of 3 quarters · filed 2026-08-05 | $25.99M 10-K · filed 2026-03-16 | |||||
| 2025-09-30 | $6.36M 10-Q · filed 2025-11-04 | $12.58M derived: sum of 2 quarters · filed 2026-08-05 | $18.02M 10-Q · filed 2025-11-04 | $25.06M derived: sum of 4 quarters · filed 2026-08-05 | |||||
| 2025-06-30 | $6.22M 10-Q · filed 2026-08-05 | $11.66M 10-Q · filed 2026-08-05 | $18.70M derived: sum of 3 quarters · filed 2026-08-05 | $25.64M derived: sum of 4 quarters · filed 2026-08-05 | |||||
| 2025-03-31 | $5.44M 10-Q · filed 2026-05-06 | $11.33M 10-Q · filed 2025-05-06 | $12.48M derived: sum of 2 quarters · filed 2026-05-06 | $19.42M derived: sum of 3 quarters · filed 2026-05-06 | $26.66M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $7.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $13.98M derived: sum of 2 quarters · filed 2026-03-16 | $21.22M derived: sum of 3 quarters · filed 2026-03-16 | $28.83M 10-K · filed 2026-03-16 | $62.41M 10-K · filed 2025-03-11 | ||||
| 2024-09-30 | $6.94M 10-Q · filed 2025-11-04 | $13.16M 10-Q · filed 2024-11-06 | $14.18M derived: sum of 2 quarters · filed 2025-11-04 | $21.79M 10-Q · filed 2025-11-04 | $48.36M 10-Q · filed 2024-11-06 | $37.07M derived: sum of 4 quarters · filed 2026-03-16 | |||
| 2024-06-30 | $7.24M 10-Q · filed 2025-08-15 | $19.22M 10-Q · filed 2024-08-06 | $14.85M 10-Q · filed 2025-08-15 | $35.20M 10-Q · filed 2024-08-06 | $30.13M derived: sum of 3 quarters · filed 2026-03-16 | $36.50M derived: sum of 4 quarters · filed 2026-03-16 | |||
| 2024-03-31 | $15.98M 10-Q · filed 2025-05-06 | $22.89M derived: sum of 2 quarters · filed 2026-03-16 | $29.26M derived: sum of 3 quarters · filed 2026-03-16 | $35.44M derived: sum of 4 quarters · filed 2026-03-16 | |||||
| 2023-12-31 | $6.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $13.28M derived: sum of 2 quarters · filed 2026-03-16 | $19.46M derived: sum of 3 quarters · filed 2026-03-16 | $25.95M 10-K · filed 2026-03-16 | |||||
| 2023-09-30 | $6.37M 10-Q · filed 2024-11-06 | $12.55M derived: sum of 2 quarters · filed 2024-11-06 | $19.04M 10-Q · filed 2024-11-06 | $26.41M derived: sum of 4 quarters · filed 2025-03-11 | |||||
| 2023-06-30 | $6.18M 10-Q · filed 2024-08-06 | $12.61M 10-Q · filed 2024-08-06 | $12.67M 10-Q · filed 2023-08-08 | $20.04M derived: sum of 3 quarters · filed 2025-03-11 | $28.52M derived: sum of 4 quarters · filed 2025-03-11 | ||||
| 2023-03-31 | $6.43M 10-Q · filed 2024-05-09 | $6.41M 10-Q · filed 2023-05-09 | $13.85M derived: sum of 2 quarters · filed 2025-03-11 | $22.34M derived: sum of 3 quarters · filed 2025-03-11 | $34.95M derived: sum of 4 quarters · filed 2025-03-11 | ||||
| 2022-12-31 | $7.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $15.91M derived: sum of 2 quarters · filed 2025-03-11 | $28.52M derived: sum of 3 quarters · filed 2025-03-11 | $37.38M 10-K · filed 2025-03-11 | $38.50M 10-K · filed 2023-03-14 | ||||
| 2022-09-30 | $8.49M 10-Q · filed 2023-11-07 | $8.65M 10-Q · filed 2022-11-09 | $21.09M derived: sum of 2 quarters · filed 2023-11-07 | $29.96M 10-Q · filed 2023-11-07 | $30.12M 10-Q · filed 2022-11-09 | $38.50M derived: sum of 4 quarters · filed 2023-11-07 | |||
| 2022-06-30 | $12.61M 10-Q · filed 2023-08-08 | $21.47M 10-Q · filed 2023-08-08 | $30.01M derived: sum of 3 quarters · filed 2023-08-08 | $39.22M derived: sum of 4 quarters · filed 2023-08-08 | |||||
| 2022-03-31 | $8.87M 10-Q · filed 2023-05-09 | $17.41M derived: sum of 2 quarters · filed 2023-05-09 | $26.61M derived: sum of 3 quarters · filed 2023-05-09 | $36.06M derived: sum of 4 quarters · filed 2023-05-09 | |||||
| 2021-12-31 | $8.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $17.75M derived: sum of 2 quarters · filed 2023-03-14 | $27.19M derived: sum of 3 quarters · filed 2023-03-14 | $37.94M 10-K · filed 2023-03-14 | |||||
| 2021-09-30 | $9.21M 10-Q · filed 2022-11-09 | $18.65M derived: sum of 2 quarters · filed 2022-11-09 | $29.40M 10-Q · filed 2022-11-09 | $40.59M derived: sum of 4 quarters · filed 2022-11-09 | |||||
| 2021-06-30 | $9.44M 10-Q · filed 2022-08-09 | $20.19M 10-Q · filed 2022-08-09 | $31.38M derived: sum of 3 quarters · filed 2022-08-09 | $39.51M derived: sum of 4 quarters · filed 2022-08-09 | |||||
| 2021-03-31 | $10.75M 10-Q · filed 2022-05-09 | $21.94M derived: sum of 2 quarters · filed 2022-05-09 | $30.07M derived: sum of 3 quarters · filed 2022-05-09 | $38.52M derived: sum of 4 quarters · filed 2022-05-09 | |||||
| 2020-12-31 | $11.19M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $19.31M derived: sum of 2 quarters · filed 2022-03-08 | $27.76M derived: sum of 3 quarters · filed 2022-03-08 | $36.46M 10-K · filed 2022-03-08 | |||||
| 2020-09-30 | $8.13M 10-Q · filed 2021-11-09 | $16.58M derived: sum of 2 quarters · filed 2021-11-09 | $25.27M 10-Q · filed 2021-11-09 | $33.55M derived: sum of 4 quarters · filed 2022-03-08 | |||||
| 2020-06-30 | $8.45M 10-Q · filed 2021-08-06 | $17.15M 10-Q · filed 2021-08-06 | $25.43M derived: sum of 3 quarters · filed 2022-03-08 | $32.55M derived: sum of 4 quarters · filed 2022-03-08 | |||||
| 2020-03-31 | $8.70M 10-Q · filed 2021-05-07 | $16.98M derived: sum of 2 quarters · filed 2022-03-08 | $24.10M derived: sum of 3 quarters · filed 2022-03-08 | $31.97M derived: sum of 4 quarters · filed 2022-03-08 | |||||
| 2019-12-31 | $8.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $15.40M derived: sum of 2 quarters · filed 2022-03-08 | $23.27M derived: sum of 3 quarters · filed 2022-03-08 | $31.64M 10-K · filed 2022-03-08 | |||||
| 2019-09-30 | $7.13M 10-Q · filed 2020-11-09 | $14.99M derived: sum of 2 quarters · filed 2020-11-09 | $23.36M 10-Q · filed 2020-11-09 | $31.32M derived: sum of 4 quarters · filed 2021-02-25 | |||||
| 2019-06-30 | $7.87M 10-Q · filed 2020-08-07 | $16.24M 10-Q · filed 2020-08-07 | $24.20M derived: sum of 3 quarters · filed 2021-02-25 | $31.63M derived: sum of 4 quarters · filed 2021-02-25 | |||||
| 2019-03-31 | $8.37M 10-Q · filed 2020-05-11 | $16.33M derived: sum of 2 quarters · filed 2021-02-25 | $23.76M derived: sum of 3 quarters · filed 2021-02-25 | $31.15M derived: sum of 4 quarters · filed 2021-02-25 | |||||
| 2018-12-31 | $7.96M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $15.39M derived: sum of 2 quarters · filed 2021-02-25 | $22.77M derived: sum of 3 quarters · filed 2021-02-25 | $30.03M 10-K · filed 2021-02-25 | |||||
| 2018-09-30 | $7.43M 10-Q · filed 2019-11-08 | $14.82M derived: sum of 2 quarters · filed 2019-11-08 | $22.07M 10-Q · filed 2019-11-08 | $29.23M derived: sum of 4 quarters · filed 2020-02-27 | |||||
| 2018-06-30 | $7.39M 10-Q · filed 2019-08-07 | $14.64M 10-Q · filed 2019-08-07 | $21.80M derived: sum of 3 quarters · filed 2020-02-27 | $29.48M derived: sum of 4 quarters · filed 2020-02-27 | |||||
| 2018-03-31 | $7.26M 10-Q · filed 2019-05-07 | $14.41M derived: sum of 2 quarters · filed 2020-02-27 | $22.10M derived: sum of 3 quarters · filed 2020-02-27 | $29.56M derived: sum of 4 quarters · filed 2020-02-27 | |||||
| 2017-12-31 | $7.16M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $14.84M derived: sum of 2 quarters · filed 2020-02-27 | $22.30M derived: sum of 3 quarters · filed 2020-02-27 | $30.83M 10-K · filed 2020-02-27 | |||||
| 2017-09-30 | $7.68M 10-Q · filed 2018-11-06 | $15.14M derived: sum of 2 quarters · filed 2018-11-06 | $23.67M 10-Q · filed 2018-11-06 | $32.44M derived: sum of 4 quarters · filed 2019-03-18 | |||||
| 2017-06-30 | $7.46M 10-Q · filed 2018-08-08 | $15.99M 10-Q · filed 2018-08-08 | $24.76M derived: sum of 3 quarters · filed 2019-03-18 | $34.01M derived: sum of 4 quarters · filed 2019-03-18 | |||||
| 2017-03-31 | $8.52M 10-Q · filed 2018-05-08 | $17.30M derived: sum of 2 quarters · filed 2019-03-18 | $26.55M derived: sum of 3 quarters · filed 2019-03-18 | $36.53M derived: sum of 4 quarters · filed 2019-03-18 | |||||
| 2016-12-31 | $8.77M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $18.02M derived: sum of 2 quarters · filed 2019-03-18 | $28.00M derived: sum of 3 quarters · filed 2019-03-18 | $38.41M 10-K · filed 2019-03-18 | |||||
| 2016-09-30 | $9.25M 10-Q · filed 2017-11-07 | $19.23M derived: sum of 2 quarters · filed 2017-11-07 | $29.64M 10-Q · filed 2017-11-07 | $39.38M derived: sum of 4 quarters · filed 2018-03-08 | |||||
| 2016-06-30 | $9.98M 10-Q · filed 2017-08-08 | $20.39M 10-Q · filed 2017-08-08 | $30.13M derived: sum of 3 quarters · filed 2018-03-08 | $39.57M derived: sum of 4 quarters · filed 2018-03-08 | |||||
| 2016-03-31 | $10.41M 10-Q · filed 2017-05-09 | $20.15M derived: sum of 2 quarters · filed 2018-03-08 | $29.60M derived: sum of 3 quarters · filed 2018-03-08 | $39.69M derived: sum of 4 quarters · filed 2018-03-08 | |||||
| 2015-12-31 | $9.74M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $19.18M derived: sum of 2 quarters · filed 2018-03-08 | $29.27M derived: sum of 3 quarters · filed 2018-03-08 | $39.26M 10-K · filed 2018-03-08 | |||||
| 2015-09-30 | $9.44M 10-Q · filed 2016-11-09 | $19.53M derived: sum of 2 quarters · filed 2016-11-09 | $29.52M 10-Q · filed 2016-11-09 | $41.24M derived: sum of 4 quarters · filed 2017-03-03 | |||||
| 2015-06-30 | $10.09M 10-Q · filed 2016-08-09 | $20.08M 10-Q · filed 2016-08-09 | $31.80M derived: sum of 3 quarters · filed 2017-03-03 | $44.48M derived: sum of 4 quarters · filed 2017-03-03 | |||||
| 2015-03-31 | $9.99M 10-Q · filed 2016-05-09 | $21.71M derived: sum of 2 quarters · filed 2017-03-03 | $34.39M derived: sum of 3 quarters · filed 2017-03-03 | $45.77M derived: sum of 4 quarters · filed 2017-03-03 | |||||
| 2014-12-31 | $11.72M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-03 | $24.40M derived: sum of 2 quarters · filed 2017-03-03 | $35.78M derived: sum of 3 quarters · filed 2017-03-03 | $43.42M 10-K · filed 2017-03-03 | |||||
| 2014-09-30 | $12.69M 10-Q · filed 2015-11-09 | $24.06M derived: sum of 2 quarters · filed 2015-11-09 | $31.71M 10-Q · filed 2015-11-09 | $37.46M derived: sum of 4 quarters · filed 2016-02-29 | |||||
| 2014-06-30 | $11.37M 10-Q · filed 2015-08-10 | $19.02M 10-Q · filed 2015-08-10 | $24.77M derived: sum of 3 quarters · filed 2016-02-29 | $29.78M derived: sum of 4 quarters · filed 2016-02-29 | |||||
| 2014-03-31 | $7.65M 10-Q · filed 2015-05-11 | $13.40M derived: sum of 2 quarters · filed 2016-02-29 | $18.41M derived: sum of 3 quarters · filed 2016-02-29 | $23.40M derived: sum of 4 quarters · filed 2016-02-29 | |||||
| 2013-12-31 | $5.75M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $10.76M derived: sum of 2 quarters · filed 2016-02-29 | $15.76M derived: sum of 3 quarters · filed 2016-02-29 | $19.95M 10-K · filed 2016-02-29 | |||||
| 2013-09-30 | $5.00M 10-Q · filed 2014-11-06 | $10.00M derived: sum of 2 quarters · filed 2014-11-06 | $14.20M 10-Q · filed 2014-11-06 | $18.46M derived: sum of 4 quarters · filed 2015-02-26 | |||||
| 2013-06-30 | $5.00M 10-Q · filed 2014-08-04 | $9.19M 10-Q · filed 2014-08-04 | $13.46M derived: sum of 3 quarters · filed 2015-02-26 | $17.53M derived: sum of 4 quarters · filed 2015-02-26 | |||||
| 2013-03-31 | $4.20M 10-Q · filed 2014-05-12 | $8.46M derived: sum of 2 quarters · filed 2015-02-26 | $12.53M derived: sum of 3 quarters · filed 2015-02-26 | $16.52M derived: sum of 4 quarters · filed 2015-02-26 | |||||
| 2012-12-31 | $4.26M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $8.34M derived: sum of 2 quarters · filed 2015-02-26 | $12.32M derived: sum of 3 quarters · filed 2015-02-26 | $16.60M 10-K · filed 2015-02-26 | |||||
| 2012-09-30 | $4.07M 10-Q · filed 2013-11-07 | $8.06M derived: sum of 2 quarters · filed 2013-11-07 | $12.34M 10-Q · filed 2013-11-07 | $16.34M derived: sum of 4 quarters · filed 2014-03-12 | |||||
| 2012-06-30 | $3.99M 10-Q · filed 2013-08-07 | $8.27M 10-Q · filed 2013-08-07 | $12.27M derived: sum of 3 quarters · filed 2014-03-12 | $15.56M derived: sum of 4 quarters · filed 2014-03-12 | |||||
| 2012-03-31 | $4.28M 10-Q · filed 2013-05-09 | $8.28M derived: sum of 2 quarters · filed 2014-03-12 | $11.57M derived: sum of 3 quarters · filed 2014-03-12 | $14.99M derived: sum of 4 quarters · filed 2014-03-12 | |||||
| 2011-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-12 | $7.29M derived: sum of 2 quarters · filed 2014-03-12 | $10.72M derived: sum of 3 quarters · filed 2014-03-12 | $13.94M 10-K · filed 2014-03-12 | |||||
| 2011-09-30 | $3.29M 10-Q · filed 2012-11-09 | $6.71M derived: sum of 2 quarters · filed 2012-11-09 | $9.94M 10-Q · filed 2012-11-09 | $12.85M derived: sum of 4 quarters · filed 2013-03-12 | |||||
| 2011-06-30 | $3.42M 10-Q · filed 2012-08-14 | $6.64M 10-Q · filed 2012-08-14 | $9.55M derived: sum of 3 quarters · filed 2013-03-12 | $13.01M derived: sum of 4 quarters · filed 2013-03-12 | |||||
| 2011-03-31 | $3.22M 10-Q · filed 2012-05-15 | $6.13M derived: sum of 2 quarters · filed 2013-03-12 | $9.59M derived: sum of 3 quarters · filed 2013-03-12 | $13.04M derived: sum of 4 quarters · filed 2013-03-12 | |||||
| 2010-12-31 | $2.91M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | $6.37M derived: sum of 2 quarters · filed 2013-03-12 | $9.82M derived: sum of 3 quarters · filed 2013-03-12 | $13.01M 10-K · filed 2013-03-12 | |||||
| 2010-09-30 | $3.46M 10-Q · filed 2011-11-14 | $6.91M derived: sum of 2 quarters · filed 2011-11-14 | $10.10M 10-Q · filed 2011-11-14 | ||||||
| 2010-06-30 | $3.45M 10-Q · filed 2011-08-09 | $6.63M 10-Q · filed 2011-08-09 | |||||||
| 2009-12-31 | $12.31M 10-K · filed 2012-03-26 | ||||||||
| 2003-12-31 | $25.00K 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |